Life sciences company specializing on progressing psychedelic therapeutics by utilizing drug discovery platforms Cybin Inc. (NEO: CYBN) (NYSE American : CYBN) announced having completed its 74th preclinical study into psychedelic molecules.
The company says it continues to progress its proprietary psychedelics molecules into Investigational New Drug (IND) enabling studies. Cybin now is looking forward to hold a research and development meeting to review these breakthrough findings before the year is over.
This meeting will be open to the media, shareholders, analysts and the public at large. The company’s research and development team says it has completed 74 in-vitro and in-vivo evaluations which will assist the company in expanding its portfolio for psychedelic compounds being designed for potential therapeutic applications for multiple mental conditions.
The company’s chief executive officer, Doug Drysdale, says they aim at creating a world class portfolio of psychedelics molecules which can become commercially viable drug candidates for both internal development and future development partnership agreements.
“Cybin continues to demonstrate superior properties of its CYB003 and CYB004 programs as we progress toward first-in-human studies, expected in early 2022. These experiments greatly expand our understanding of the potential therapeutic value of the studied compounds and further demonstrate Cybin’s strong research and development capabilities,” added the CEO.